Compound Evidence File
#EC-2026-0080
Ivermectin
Filed under Oral Tablets. The bureau holds 154 laboratory returns for this compound from 57 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
57 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| WuXi TIDESCASE #VI-2026-0335 | A | 5 | 10.0 | 9.9 | 10.0 | 11 Apr 2026 | 22 Jun 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 4 | 10.0 | 9.9 | 10.0 | 6 May 2026 | 9 Jun 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 3 | 10.0 | 9.9 | 10.0 | 1 Apr 2026 | 10 Jun 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 3 | 10.0 | 9.9 | 10.0 | 6 Feb 2026 | 10 Jul 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 3 | 10.0 | 10.0 | 10.0 | 10 Dec 2025 | 5 Jul 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 3 | 10.0 | 9.9 | 10.0 | 4 Jan 2026 | 28 Jun 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 3 | 10.0 | 9.9 | 10.0 | 17 Apr 2026 | 8 Aug 2026 |
| SinoPepCASE #VI-2026-0387 | A | 3 | 10.0 | 9.9 | 10.0 | 12 Dec 2025 | 9 Aug 2026 |
| BachemCASE #VI-2026-0314 | A | 2 | 10.0 | 10.0 | 10.0 | 1 Apr 2026 | 4 Apr 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 2 | 10.0 | 10.0 | 10.0 | 16 May 2026 | 9 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 2 | 10.0 | 10.0 | 10.0 | 13 May 2026 | 8 Jun 2026 |
| LipeptidesCASE #VI-2026-0863 | X | 1 | 10.0 | 10.0 | 10.0 | 16 Mar 2025 | 16 Mar 2025 |
| NUPEPS PeptidesCASE #VI-2026-0896 | X | 1 | 10.0 | 10.0 | 10.0 | 2 Apr 2025 | 2 Apr 2025 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 5 | 9.9 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 4 | 9.9 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 4 | 9.9 | 9.9 | 10.0 | 12 Nov 2025 | 1 Jun 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 4 | 9.9 | 9.9 | 10.0 | 28 Dec 2025 | 28 Jun 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 4 | 9.9 | 9.9 | 10.0 | 16 Feb 2026 | 25 Jul 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 4 | 9.9 | 9.9 | 10.0 | 7 Jan 2026 | 3 Jul 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 3 | 9.9 | 9.9 | 10.0 | 26 Apr 2026 | 24 Jun 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 2 | 9.9 | 9.9 | 10.0 | 16 Feb 2026 | 7 Jul 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 2 | 9.9 | 9.9 | 9.9 | 15 Feb 2026 | 16 Apr 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 2 | 9.9 | 9.9 | 10.0 | 18 Jun 2026 | 1 Jul 2026 |
| AsymchemCASE #VI-2026-0091 | A | 2 | 9.9 | 9.9 | 10.0 | 5 Jun 2026 | 21 Jun 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 2 | 9.9 | 9.9 | 9.9 | 12 Jul 2026 | 8 Aug 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 7 | 9.4 | 8.7 | 10.0 | 23 May 2026 | 23 May 2026 |
| Xingtai Lesda TechnologyCASE #VI-2026-0381 | X | 1 | 9.1 | 9.1 | 9.1 | 3 Jul 2025 | 3 Jul 2025 |
| Precision Peptide CoCASE #VI-2026-0559 | X | 1 | 9.0 | 9.0 | 9.0 | 11 Jun 2025 | 11 Jun 2025 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 7 | 8.5 | 7.4 | 10.0 | 24 May 2026 | 24 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 3 | 8.5 | 7.2 | 10.0 | 24 May 2026 | 24 May 2026 |
| Peptide PartnersCASE #VI-2026-0295 | X | 6 | 8.5 | 6.0 | 10.0 | 7 May 2025 | 21 May 2026 |
| Rayshine Peptide BiochemicalsCASE #VI-2026-0545 | X | 1 | 8.5 | 8.5 | 8.5 | 17 Dec 2024 | 17 Dec 2024 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 4 | 8.3 | 7.7 | 9.0 | 21 May 2026 | 21 May 2026 |
| Bfflist AMOCASE #VI-2026-0678 | X | 3 | 8.3 | 6.8 | 9.7 | 9 Jun 2025 | 23 May 2026 |
| Aavant ResearchCASE #VI-2026-0831 | X | 1 | 8.1 | 8.1 | 8.1 | 21 May 2025 | 21 May 2025 |
| BfflinkCASE #VI-2026-0212 | X | 1 | 7.9 | 7.9 | 7.9 | 28 Mar 2025 | 28 Mar 2025 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 2 | 7.5 | 7.5 | 7.6 | 25 May 2026 | 25 May 2026 |
| Henan Sahe PeptideCASE #VI-2026-0894 | X | 1 | 7.5 | 7.5 | 7.5 | 8 Jul 2025 | 8 Jul 2025 |
| Reta-PeptideCASE #VI-2026-0756 | X | 8 | 7.3 | 6.1 | 9.0 | 2 Jul 2025 | 21 May 2026 |
| BeiBangAnCASE #VI-2026-0899 | X | 1 | 7.3 | 7.3 | 7.3 | 2 Apr 2025 | 2 Apr 2025 |
| LiliPeptideCASE #VI-2026-0695 | X | 9 | 7.1 | 4.2 | 10.0 | 11 Jun 2025 | 23 May 2026 |
| Shandong Shengyuan Peptide TechnologyCASE #VI-2026-0634 | X | 1 | 6.9 | 6.9 | 6.9 | 28 Mar 2025 | 28 Mar 2025 |
| EHZ PeptidesCASE #VI-2026-0296 | C | 3 | 6.6 | 6.2 | 7.0 | 9 Jun 2025 | 26 Jan 2026 |
| Paramount PeptidesCASE #VI-2026-0550 | X | 6 | 6.4 | 4.6 | 8.4 | 3 Jul 2025 | 21 May 2026 |
| Qingdao Saber Technology Pharma QSTCASE #VI-2026-0467 | X | 1 | 6.2 | 6.2 | 6.2 | 9 Jun 2025 | 9 Jun 2025 |
| Biolongevity LabsCASE #VI-2026-0442 | X | 3 | 6.0 | 4.3 | 7.2 | 13 Jun 2025 | 24 May 2026 |
| Yongkang Nuoao Trading CoCASE #VI-2026-0646 | X | 1 | 6.0 | 6.0 | 6.0 | 3 Jul 2025 | 3 Jul 2025 |
| Liberty PeptidesCASE #VI-2026-0416 | X | 1 | 5.7 | 5.7 | 5.7 | 28 Mar 2025 | 28 Mar 2025 |
| Diju Peptides Wellness and CoCASE #VI-2026-0724 | X | 1 | 5.6 | 5.6 | 5.6 | 20 Jun 2025 | 20 Jun 2025 |
| Dragon PharmaCASE #VI-2026-0519 | X | 1 | 5.6 | 5.6 | 5.6 | 17 Dec 2024 | 17 Dec 2024 |
| Prime PeptidesCASE #VI-2026-0696 | X | 1 | 5.4 | 5.4 | 5.4 | 20 Jun 2025 | 20 Jun 2025 |
| Golden EagleCASE #VI-2026-0680 | X | 1 | 5.3 | 5.3 | 5.3 | 28 Mar 2025 | 28 Mar 2025 |
| PeptidologyCASE #VI-2026-0520 | X | 1 | 5.0 | 5.0 | 5.0 | 21 May 2025 | 21 May 2025 |
| Evolve BioPepCASE #VI-2026-0755 | X | 1 | 5.0 | 5.0 | 5.0 | 2 Jul 2025 | 2 Jul 2025 |
| Champion PeptideCASE #VI-2026-0909 | X | 1 | 4.2 | 4.2 | 4.2 | 8 Jul 2025 | 8 Jul 2025 |
| Peptide ArkCASE #VI-2026-0350 | X | 1 | 1.8 | 1.8 | 1.8 | 7 May 2025 | 7 May 2025 |
| LOOKBiotechCASE #VI-2026-0807 | X | 1 | 1.2 | 1.2 | 1.2 | 13 Jun 2025 | 13 Jun 2025 |
Open any subject to view the batch-level evidence for Ivermectin alone.